AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On June 12, 2025, Beigene's trading volume reached 2.01 billion, marking a significant 172.82% increase from the previous day. This surge placed
at the 434th position in the daily stock market rankings.BeOne Medicines, a subsidiary of Beigene, is set to host an investor R&D Day on June 26, 2025. During this event, the company will discuss its global hematology pipeline and future plans, providing insights into its ongoing research and development efforts.
Beigene, Ltd. recently announced its quarterly earnings results, reporting an earnings per share (EPS) of $1.22 for the quarter. This figure exceeded analysts' expectations, highlighting the company's strong financial performance.
The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BeOne's BRUKINSA, a significant development for the company's oncology portfolio. This approval expands the availability and convenience of BRUKINSA for patients, potentially driving further growth in the company's revenue.
BeOne Medicines has recently launched following its redomiciliation to Switzerland, marking a new chapter in its global oncology efforts. This strategic move is expected to enhance the company's operational efficiency and market reach, positioning it for future growth and innovation.
Hunt down the stocks with explosive trading volume.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet